CA2390685C - Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique - Google Patents

Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique Download PDF

Info

Publication number
CA2390685C
CA2390685C CA002390685A CA2390685A CA2390685C CA 2390685 C CA2390685 C CA 2390685C CA 002390685 A CA002390685 A CA 002390685A CA 2390685 A CA2390685 A CA 2390685A CA 2390685 C CA2390685 C CA 2390685C
Authority
CA
Canada
Prior art keywords
acid sequence
pro
amino acid
alternatively
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002390685A
Other languages
English (en)
Other versions
CA2390685A1 (fr
Inventor
Avi J. Ashkenazi
Audrey Goddard
Austin L. Gurney
Mary A. Napier
Colin K. Watanabe
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/000376 external-priority patent/WO2000053755A2/fr
Priority claimed from PCT/US2000/004342 external-priority patent/WO2000078961A1/fr
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/fr
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2390685A1 publication Critical patent/CA2390685A1/fr
Application granted granted Critical
Publication of CA2390685C publication Critical patent/CA2390685C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte à des procédés et à des compositions permettant d'inhiber la croissance cellulaire néoplasique. Elle se rapporte notamment à des compositions antitumorales et à des méthodes de traitement des tumeurs. L'invention se rapporte également à des méthodes de criblage permettant d'identifier des composés inhibiteurs de croissance, notamment des composés antitumoraux. La présente invention se rapporte à des polypeptides et à des molécules d'acides nucléiques codant lesdits polypeptides. Elle se rapporte en outre à des vecteurs et à des cellules hôtes comportant ces séquences d'acides nucléiques, à des molécules polypeptidiques chimères comportant les polypeptides de la présente invention accolés à des séquences polypeptidiques hétérologues, à des anticorps qui se lient aux polypeptides de la présente invention et à des procédés de production des polypeptides ci-dessus décrits.
CA002390685A 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique Expired - Lifetime CA2390685C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
USPCT/US00/00376 2000-01-06
PCT/US2000/000376 WO2000053755A2 (fr) 1999-03-08 2000-01-06 Compositions et procedes pour le traitement de tumeur
USPCT/US00/04342 2000-02-18
PCT/US2000/004342 WO2000078961A1 (fr) 1999-06-23 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
USPCT/US00/05841 2000-03-02
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
USPCT/US00/08439 2000-03-30
PCT/US2000/020710 WO2001009327A2 (fr) 1999-07-28 2000-07-28 Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
USPCT/US00/20710 2000-07-28
PCT/US2000/030952 WO2001049715A2 (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique

Publications (2)

Publication Number Publication Date
CA2390685A1 CA2390685A1 (fr) 2001-07-12
CA2390685C true CA2390685C (fr) 2008-04-22

Family

ID=27533357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002390685A Expired - Lifetime CA2390685C (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique

Country Status (4)

Country Link
EP (1) EP1244784A2 (fr)
JP (1) JP4280444B2 (fr)
CA (1) CA2390685C (fr)
WO (1) WO2001049715A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083791B2 (en) 1999-03-25 2006-08-01 Genesis Research & Development Corporation Limited Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
US6797271B2 (en) 1999-03-25 2004-09-28 Genesis Research & Development Corporation Limited Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
US7247717B2 (en) 2000-11-14 2007-07-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003287918A1 (en) 2002-12-20 2004-07-14 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
WO1991017183A1 (fr) * 1990-04-27 1991-11-14 Takeda Chemical Industries, Ltd. Proteines presentant une activite de recepteur de facteur de croissance de fibroblaste
WO2000073454A1 (fr) * 1999-06-02 2000-12-07 Genentech, Inc. Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
WO2000053755A2 (fr) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions et procedes pour le traitement de tumeur
IL139686A0 (en) * 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001000803A2 (fr) * 1999-06-25 2001-01-04 Genset Proteine associee a l'apolipoproteine a-iv (aa4rp): sequences polypeptidiques, polynucleotidiques et marqueurs bialleliques de ces dernieres
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
AU6391000A (en) * 1999-07-28 2001-02-19 Genentech Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases

Also Published As

Publication number Publication date
JP4280444B2 (ja) 2009-06-17
EP1244784A2 (fr) 2002-10-02
WO2001049715A2 (fr) 2001-07-12
WO2001049715A3 (fr) 2002-04-04
JP2004500071A (ja) 2004-01-08
CA2390685A1 (fr) 2001-07-12

Similar Documents

Publication Publication Date Title
AU768230B2 (en) Methods and compositions for inhibiting neoplastic cell growth
CA2373915A1 (fr) Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
CA2441902A1 (fr) Immunoadhesines d'erythropoietine de chimpanze (chepo)
WO2000075327A1 (fr) Methodes et compositions d'inhibition de croissance cellulaire neoplasique
CA2390685C (fr) Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
ZA200103885B (en) Methods and compositions for inhibiting neoplastic cell growth.
US20020010137A1 (en) Methods and compositions for inhibiting neoplastic cell growth
AU3107000A (en) Methods and compositions for inhibiting neoplastic cell growth
AU758462B2 (en) Methods and compositions for inhibiting neoplastic cell growth
AU2003213166B2 (en) Novel polypeptides having sequence similarity to GDNFR and nucleic acids encoding the same
WO2000075316A1 (fr) Procedes et compositions pour l'inhibition de la croissance de cellules neoplastiques
AU2003204815B2 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2000053751A1 (fr) Procedes et compositions pour l'inhibition de la croissance de cellules neoplasiques
AU2003257515B2 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1820859B9 (fr) Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
US20100285016A1 (en) PRO34128 nucleic acids
WO2000055319A1 (fr) Procedes et compositions pour inhiber la croissance des cellules neoplasiques
EP1518930A2 (fr) Procédés et compositions inhibant la croissance des cellules néoplastiques
ZA200103883B (en) Method and compositions for inhibiting neoplastic cell growth.
JP2007238619A (ja) 腫瘍性細胞成長阻害のための組成物及び方法

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201109